A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
Document title: A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
Journal: Revista de investigación clínica
Database: PERIÓDICA
System number: 000453008
ISSN: 0034-8376
Authors: 1
1
1
1
2
1
1
1
Institutions: 1Instituto Nacional de Cancerología, División de Investigación, Ciudad de México. México
2Instituto Nacional de Cancerología, Departamento de Patología, Ciudad de México. México
3Universidad Nacional Autónoma de México, Instituto de Investigaciones Biomédicas, Ciudad de México. México
Year:
Season: Nov-Dic
Volumen: 73
Number: 6
Pages: 362-370
Country: México
Language: Inglés
Document type: Artículo
Approach: Experimental, aplicado
English abstract Background: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. Methods: In a cohort of patients with DLBCL treated between 2015 and 2017, we analyzed the presence of EZH2 mutations and their association with clinical response (CR), relapse, progression-free survival (PFS), and overall survival (OS). Results: A total of 198 patients were included; of them, 30 (15.2%) had mutations at codon 641, in exon 16 of EZH2. Response was achieved in 151 patients (76.3%), and 43 (21.7%) relapsed or progressed during follow-up. EZH2 mutations were associated with relapse/progression (risk ratio [RR] 1.18; 95% confidence interval [CI] 0.98–1.42; p = 0.031), while a trend for not achieving a complete response was observed (RR: 0.876; 95%CI 0.74–1.038; p = 0.071). Of note, Tyr641His and Tyr641Ser EZH2 mutations were associated with shorter PFS (hazard ratio 3.234; 95% CI 1.149–9.1; p = 0.026). Conclusion: The presence of EZH2 mutations was negatively associated with relapse/progression and showed a trend for lack of complete response. Further studies are needed to define better the prognostic significance of these mutations in Mexican-Mestizo DLBCL patients
Disciplines: Medicina
Keyword: Oncología,
Genética,
Linfoma difuso de células B,
Mutaciones,
Rituximab,
Sobrevivencia
Keyword: Oncology,
Genetics,
Diffuse large B-cell lymphoma,
Mutations,
Rituximab,
Survival
Full text: Texto completo (Ver HTML) Texto completo (Ver PDF)